［1］ROBERTS M，AYNARDI J，CHU C.Uterine leiomyosarcoma：A review of the literature and update on management options［J］.Gynecol Oncol，2018，151(3)：562-572.
［2］周琦，吴小华，刘继红，等.子宫肉瘤诊断与治疗指南（第四版）［J］.中国实用妇科与产科杂志，2018，34(10)：1106-1110.
ZHOU Q，WU XH，LIU JH，et al.Guidelines for diagnosis and treatment of uterine sarcomas(version 4)［J］.Chinese Journal of Practical Gynecology and Obsterics，2018，34(10)：1106-1110.
［3］SEAGLE B，SOBECKI-RAUSCH J，STROHL A，et al.Prognosis and treatment of uterine leiomyosarcoma：A national cancer database study［J］.Gynecol Oncol，2017，145(1)：61-70.
［4］BARTOSCH C，AFONSO M，PIRES-LUIS AS，et al.Distant metastases in uterine leiomyosarcomas：The wide variety of body sites and time intervals to metastatic relapse［J］.Int J Gynecol Pathol，2017，36(1)：31-41.
［5］HINCHCLIFF EM，ESSELEN KM，WATKINS JC，et al.The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma［J］.J Minim Invasive Gynecol，2016，23(4)：567-572.
［6］PETERS A，SADECKY AM，WINGER DG，et al.Characterization and preoperative risk analysis of leiomyosarcomas at a high-volume tertiary care center［J］.Int J Gynecol Cancer，2017，27(6)：1183-1190.
［7］GADDUCCI A，LANDONI F，SARTORI E，et al.Uterine leiomyosarcoma：analysis of treatment failures and survival［J］.Gynecol Oncol，1996，62(1)：25-32.
［8］谢玲玲，林荣春，林仲秋.《2021NCCN子宫肿瘤临床实践指南（第1版）》解读［J］.中国实用妇科与产科杂志，2021，36(4)：333-339.
XIE LL，LIN RC，LIN ZQ.Interpretation of 2021 NCCN clinical practice guidelines of uterine tumors(version 1).［J］.Chinese Journal of Practical Gynecology and Obsterics，2021，36(4)：333-339.
［9］WU CQ，WOO LY，GIEDE KC，et al.Occult leiomyosarcomas in a canadian province：A retrospective cohort study［J］.J Obstet Gynaecol Can，2019，41(1)：46-51.
［10］RASPAGLIESI F，MALTESE G，BOGANI G，et al.Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas：A retrospective MITO group study［J］.Gynecol Oncol，2017，144(1)：90-95.
［11］BOGANI G，CHIAPPA V，DITTO A，et al.Morcellation of undiagnosed uterine sarcoma：A critical review［J］.Crit Rev Oncol Hematol，2016，98：302-308.
［12］AAMIG W.AAGL practice report：Morcellation during uterine tissue extraction［J］.J Minim Invasive Gynecol，2014，21(4)：517-530.
［13］BROWN J.AAGL advancing minimally invasive gynecology worldwide：statement to the FDA on power morcellation［J］.J Minim Invasive Gynecol，2014，21(6)：970-971.
［14］JUHASZ-BOSS I，GABRIEL L，BOHLE RM，et al.Uterine leiomyosarcoma［J］.Oncology Research and Treatment，2018，41(11)：680-686.
［15］LEITAO M，SONODA Y，BRENNAN M，et al.Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus［J］.Gynecol Oncol，2003，91(1)：209-212.
［16］GIUNTOLI RL，METZINGER DS，DIMARCO CS，et al.Retrospective review of 208 patients with leiomyosarcoma of the uterus：prognostic indicators，surgical management，and adjuvant therapy［J］.Gynecol Oncol，2003，89(3)：460-469.
［17］NASIOUDIS D，CHAPMAN-DAVIS E，FREY M，et al.Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma［J］.J Gynecol Oncol，2017，28(4)：e46.
［18］KAPP DS，SHIN JY，CHAN JK.Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas：emphasis on impact of lymphadenectomy and oophorectomy［J］.Cancer，2008，112(4)：820-830.
［19］LEVENBACK CF，TORTOLERO-LUNA G FAU-PANDEY DK，PANDEY DK FAU-MALPICA A，et al.Uterine sarcoma［J］.Obstet Gynecol Clin North Am，1996，23(2)：457-473.
［20］TIRUMANI SH，DEAVER P，SHINAGARE AB，et al.Metastatic pattern of uterine leiomyosarcoma：retrospective analysis of the predictors and outcome in 113 patients［J］.J Gynecol Oncol，2014，25(4)：306-312.
［21］TAKEHARA K，YAMASHITA N，WATANABE R，et al.Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma［J］.Gynecol Oncol，2020，157(1)：115-120.
［22］MBATANI N，OLAWAIYE AB，PRAT J.Uterine sarcomas［J］.Int J Gynaecol Obstet，2018,143(Suppl 2)：51-58.
［23］COSTALES AB，RADEVA M，RICCI S.Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage(uterine confined) leiomyosarcoma：A national cancer database study［J］.J Gynecol Oncol，2020，31(3)：e21.
［24］LITTELL RD，TUCKER LY，RAINE-BENNETT T，et al.Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma：Trends and survival outcomes［J］.Gynecol Oncol，2017，147(1)：11-17.
［25］HENSLEY ML，WATHEN JK，MAKI RG，et al.Adjuvant therapy for high-grade，uterus-limited leiomyosarcoma：results of a phase 2 trial(SARC 005)［J］.Cancer，2013，119(8)：1555-1561.
［26］RIZZO A，PANTALEO MA，SAPONARA M，et al.Current status of the adjuvant therapy in uterine sarcoma：A literature review［J］.World J Clin Cases，2019，7(14)：1753-1763.
［27］FRIEDMAN CF，HENSLEY ML.Options for adjuvant therapy for uterine leiomyosarcoma［J］.Curr Treat Options Oncol，2018，19(2)：7.
［28］REED NS，MANGIONI C，MALMSTROM H，et al.Phase Ⅲ randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages Ⅰ and Ⅱ：an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study(protocol 55874)［J］.Eur J Cancer，2008，44(6)：808-818.
［29］PAUTIER P，FLOQUET A，GLADIEFF L，et al.A randomized clinical trial of adjuvant chemotherapy with doxorubicin，ifosfamide，and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas(SARCGYN study).A study of the French Sarcoma Group［J］.Ann Oncol，2013，24(4)：1099-1104.
［30］GEORGE S，FENG Y，MANOLA J，et al.Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors［J］.Cancer，2014，120(5)：738-743.
［31］DAVIDSON B，KJARENG ML，FORSUND M，et al.Progesterone receptor expression is an independent prognosticator in FIGO stage Ⅰ uterine leiomyosarcoma［J］.Am J Clin Pathol，2016，145(4)：449-458.
［32］ZANG Y，DONG M，ZHANG K，et al.Hormonal therapy in uterine sarcomas［J］.Cancer Med，2019，8(4)：1339-1349.
［33］IOFFE YJ，LI AJ，WALSH CS，et al.Hormone receptor expression in uterine sarcomas：prognostic and therapeutic roles［J］.Gynecol Oncol，2009，115(3)：466-471.
［34］LO CA，HUANG SC，HO CL，et al.Discordant responses to progestin in a patient with uterine low-grade smooth-muscle tumors metastatic to the lung［J］.J Obstet Gynaecol Res，2005，31(5)：394-398.
［35］BAEK MH，PARK JY，PARK Y，et al.Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma［J］.J Gynecol Oncol，2018，29(3)：e30.
［36］RIJS Z，SHIFAI AN，BOSMA SE，et al.Candidate biomarkers for specific intraoperative near-infrared imaging of soft tissue sarcomas：A systematic review［J］.Cancers(Basel)，2021，13(3)：557
［37］MAKI RG，D'ADAMO DR，KEOHAN ML，et al.Phase Ⅱ study of sorafenib in patients with metastatic or recurrent sarcomas［J］.J Clin Oncol，2009，27(19)：3133-3140.
［38］TAP WD，JONES RL，VAN TINE BA，et al.Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma：an open-label phase 1b and randomised phase 2 trial［J］.Lancet，2016，388(10043)：488-497.
［39］SHIRLEY M.Olaratumab：First global approval［J］.Drugs，2017，77(1)：107-112.
［40］VAN DER GRAAF WT，BLAY JY，CHAWLA SP，et al.Pazopanib for metastatic soft-tissue sarcoma(PALETTE)：a randomised，double-blind，placebo-controlled phase 3 trial［J］.Lancet，2012，379(9829)：1879-1886.
［41］KIM HJ，KIM Y，LEE SJ，et al.Pazopanib monotherapy in the treatment of pretreated，metastatic uterine sarcoma：a single-center retrospective study［J］.J Gynecol Oncol，2018，29(1)：e3.
［42］PAOLUZZI L，CACAVIO A，GHESANI M，et al.Response to anti-PD1 therapy with nivolumab in metastatic sarcomas［J］.Clin Sarcoma Res，2016，6：24.
［43］TAWBI HA，BURGESS M，BOLEJACK V，et al.Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma(SARC028)：a multicentre，two-cohort，single-arm，open-label，phase 2 trial［J］.Lancet Oncol，2017，18(11)：1493-1501.
［44］OMURA GA，BLESSING JA，MAJOR F，et al.A randomized clinical trial of adjuvant adriamycin in uterine sarcomas：A Gynecologic Oncology Group Study［J］.J Clin Oncol，1985，3(9)：1240-1245.